Australia markets open in 1 hour 15 minutes

Aclaris Therapeutics, Inc. (8AT.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.1065-0.0845 (-7.09%)
At close: 08:00AM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 77.35M
Enterprise value -32.75M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.66
Price/book (mrq)0.54
Enterprise value/revenue 9.84
Enterprise value/EBITDA -3.47

Trading information

Stock price history

Beta (5Y monthly) 0.24
52-week change 3-90.66%
S&P500 52-week change 326.27%
52-week high 311.8450
52-week low 30.5900
50-day moving average 31.1108
200-day moving average 33.8221

Share statistics

Avg vol (3-month) 359
Avg vol (10-day) 3N/A
Shares outstanding 571.26M
Implied shares outstanding 673.45M
Float 850.92M
% held by insiders 12.49%
% held by institutions 191.44%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -248.28%
Operating margin (ttm)-672.69%

Management effectiveness

Return on assets (ttm)-31.90%
Return on equity (ttm)-48.47%

Income statement

Revenue (ttm)31.12M
Revenue per share (ttm)0.44
Quarterly revenue growth (yoy)-5.10%
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-77.26M
Diluted EPS (ttm)-1.1800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)128.17M
Total cash per share (mrq)1.8
Total debt (mrq)3.47M
Total debt/equity (mrq)2.45%
Current ratio (mrq)6.74
Book value per share (mrq)1.99

Cash flow statement

Operating cash flow (ttm)-72.79M
Levered free cash flow (ttm)-40.25M